Regenerative Medical Technology Group Inc.

Regenerative Medical Technology Group Inc.

OOTC:RMTG
0.03
USD
0.00
(0.00%)
-0.73EPS
604,392.53Market Cap

Total Valuation

USD

As of June 30, 2026, Regenerative Medical Technology Group Inc. carries a market capitalization of 604,392.53, placing it among publicly traded companies globally. Its enterprise value stands at 21.02M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap604,392.53
Enterprise Value21.02M

Share Statistics

As of June 30, 2026, Regenerative Medical Technology Group Inc. has 13.14M shares outstanding.

Shares Outstanding13.14M

Valuation Ratios

These figures are as of June 30, 2026. The price-to-sales ratio is 0.06, and the price-to-book ratio stands at -0.02.

PS Ratio0.06
PB Ratio-0.02
P/TBV Ratio-0.01
P/FCF Ratio-1.03
P/OCF Ratio2.23

Enterprise Valuation

As of June 30, 2026, Regenerative Medical Technology Group Inc. trades at an EV/EBITDA multiple of 51.70 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.23 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 480.79 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 21.02M versus a market cap of 604,392.53, with the gap driven by net debt and cash on the balance sheet.

EV / Sales2.23
EV / EBITDA51.70
EV / EBIT480.79

Financial Position

As of June 30, 2026, Regenerative Medical Technology Group Inc. maintains a current ratio of 0.05, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -55.38, indicating conservative leverage, while an interest coverage ratio of 0.04 demonstrates limited ability to service its debt obligations.

Current Ratio0.05
Quick Ratio0.03
Debt / Equity-55.38
Debt / EBITDA53.46
Interest Coverage0.04

Financial Efficiency

USD

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -184.36, reflecting losses generated across the asset base. The company generates approximately 9.41M in revenue per employee across its workforce of 1.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 12.91 indicates how many times Regenerative Medical Technology Group Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Assets (ROA)-184.36
Revenue Per Employee9.41M
Employee Count1.00
Inventory Turnover12.91

Stock Price Statistics

USD

As of the close on November 16, 2026, Regenerative Medical Technology Group Inc.'s stock has declined approximately 31.82% over the past 52 weeks. The 50-day moving average sits at 0.06, while the 200-day moving average is 0.05.

52-Week Price Change-31.82%
50-Day Moving Average0.06
200-Day Moving Average0.05

Income Statement

USD

Over the twelve months ended June 30, 2026, Regenerative Medical Technology Group Inc. generated 9.41M in revenue and converted that into -9.53M in net income, yielding earnings per share of -0.73. EBITDA reached 406,650.00, while operating income came in at 43,725.00.

Revenue9.41M
Gross Profit5.63M
Operating Income43,725.00
Pretax Income-9.53M
Net Income-9.53M
EBITDA406,650.00
EBIT43,725.00
Earnings Per Share (EPS)-0.73

Balance Sheet

USD

As of June 30, 2026, Regenerative Medical Technology Group Inc. holds 1.32M in cash and equivalents against 21.74M in total debt, resulting in a net debt position of 19.77M. Total book value stands at -39.26M, with working capital of -40.33M providing operational flexibility.

Cash & Cash Equivalents1.32M
Total Debt21.74M
Net Debt19.77M
Equity (Book Value)-39.26M
Book Value Per Share-2.99
Working Capital-40.33M

Cash Flow

USD

Regenerative Medical Technology Group Inc. produced 268,563.00 in operating cash flow over the twelve months ended June 30, 2026. After subtracting -850,894.00 in capital expenditures, free cash flow totaled -582,331.00 - equivalent to -0.04 per share.

Operating Cash Flow268,563.00
Capital Expenditures-850,894.00
Free Cash Flow-582,331.00
FCF Per Share-0.04

Margins

Over the twelve months ended June 30, 2026, Regenerative Medical Technology Group Inc. posted a gross margin of 59.76, reflecting its pricing power and cost economics. The operating margin of 0.46 and net profit margin of -101.21 provide insight into operational efficiency.

Gross Margin59.76
Operating Margin0.46
Pretax Margin-101.21
Profit Margin-101.21
EBITDA Margin4.32

Dividends & Yields

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -97.39: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -48.21, meaning Regenerative Medical Technology Group Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-48.21
FCF Yield-97.39

Stock Splits

Regenerative Medical Technology Group Inc.'s most recent stock split took place on September 26, 2018 with a 1000:1 split ratio.

Last Split Date9/26/2018
Split Ratio1000:1

Scores

As of June 30, 2026, Regenerative Medical Technology Group Inc. has an Altman Z-Score of -36.10, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-36.10